Eli Lilly Warns Against Loss of Pharmaceutical Jobs in Germany

Eli Lilly and Company has offered to help build a new level of trust between the biopharmaceutical industry and government health care regulators in Germany.John C. Lechleiter, Ph.D., chairman, president and chief executive officer of Eli Lilly and Company, stated the same recently in an address to the Federation of German Industries Conference in Germany.Lechleiter mentioned that although the company is based in the US, it has “deep roots” in Germany and “enormous respect for this country’s legacy as a pharmaceutical powerhouse”.“However, in no other place in the world has the environment for innovative pharmaceuticals changed more in the last 12 months than it has in Germany, he said, noting that recent health care reforms are jeopardising the country’s legacy of pharmaceutical innovation. He further added, “At the same time, I see Germany as a place where the pharmaceutical industry can achieve a breakthrough – a fresh start if you will – to develop more constructive and collaborative relationships.”Lilly’s German headquarters are in Bad Homburg and it packages and distributes Lilly products to more than 90 countries in Europe, the Middle East, and Africa from its manufacturing facility in Giessen. The company is currently conducting more than 120 clinical trials in the country alone, involving more than 14,000 patients and testing 26 potential new medicines.